Ted patients, the effects of PPARc C1431T polymorphism on Tubastatin-A site metabolic syndrome varied in different studies, the majority of them indicated the association of C1431T polymorphism with obesity and hyperglycemia. For example, in a Finnish study, obese women with the TT genotype had an increased BMI and waist circumference [39]. Similarly, in Chinese population, the CT and TT genotypes in C1431T polymorphism have been associated with a higher fasting blood sugar in patients with metabolic syndrome [35]. However, in an Asian population, the CT and TT genotypes had a lower risk of diabetes, but a higher BMI than those with the CC genotypeTable 4. Multivariate analysis of factors associated with serum triglyceride .150 mg/dl, serum cholesterol .200 mg/dl, or HOMA index .3.8.Genetic polymorphismstriglyceride .150 mg/dl Odds ratio 95 CI 0.087,0.921 0.081,3.583 0.373,10.cholesterol .200 mg/dlHOMA index .3.P value0.04 0.52 0.Odds ratio 1.360 7.373 0.95 CI 0.472,3.920 0.667,81.524 0.255,3.P value Odds ratio0.57 0.10 0.93 0.272 0.751 8.95 CI 0.049,1.517 0.112,5.063 1.573,49.P value0.14 0.77 0.PPARc C1430T (TC+TT) PPARc Pro12Ala (Pro/Ala) RBP4 2803GA (GA+AA)0.282 0.539 1.Variables of multivariate analysis include gender, age, C1430T polymorphism, P12A polymorphism, RBP4 polymorphism, hazardous drinking, HCV co-infection, calorie over-TEE, and efavirenz use. CI denotes confidence interval. doi:10.1371/journal.pone.0049102.tPPARc and RBP4 SNP on Metabolism in HIV Patients[14]. In HIV-infected patients, the association of C1431T polymorphism with metabolic syndrome is not well documented. For example, Nazih et al. found there was no convincing association between the His449His (equal to C1431T) polymorphism and individual components of the metabolic syndrome [40]. In the study by Zanone et al., the C161T (equal to C1431T) polymorphism had no influence on the presence of atrophy and fat accumulation in individuals with HIV-related lipodystrophy [41]. In our study, we found that the T allele of PPARc C1431T polymorphism was marginally associated with a lower rate of hypertriglyceridemia in HIV-infected patients receiving antiretroviral therapy in univariate and multivariate analyses. However, it did not reach a desirable power in the post hoc analysis and statistical significance after the correction for multiple testing. Finally, the statistical significance (0.006) with a nearly acceptable power (0.79) indicates that the T allele carriers have lower serum triglyceride levels at several time points of the Z-360 cost longitudinal followup. There are many reasons to reduce the power of mixed models. For example: smaller sample size, lower number of repeated measures, higher between-subject variance, higher intraclass correlation, and smaller difference between two groups, and so on. Thus, the effect of PPARc C1431T polymorphism on serum triglyceride in HIV-infected patients is not significant and requires further large scale study. The Pro12Ala polymorphism in PPARc represents the first genetic variant with a broad impact on the risk and complications of type 2 diabetes. In vitro studies showed that Ala variant exhibited moderate reduction of target gene transactivation due to decreased DNA binding capacity [13]. The effect of the Ala carriage is not conclusive in the literature both in non HIV-infected and in HIVinfected patients. While most studies in non HIV-infected patients found that the Ala carrier exerted a protective effect from development of type 2 diabet.Ted patients, the effects of PPARc C1431T polymorphism on metabolic syndrome varied in different studies, the majority of them indicated the association of C1431T polymorphism with obesity and hyperglycemia. For example, in a Finnish study, obese women with the TT genotype had an increased BMI and waist circumference [39]. Similarly, in Chinese population, the CT and TT genotypes in C1431T polymorphism have been associated with a higher fasting blood sugar in patients with metabolic syndrome [35]. However, in an Asian population, the CT and TT genotypes had a lower risk of diabetes, but a higher BMI than those with the CC genotypeTable 4. Multivariate analysis of factors associated with serum triglyceride .150 mg/dl, serum cholesterol .200 mg/dl, or HOMA index .3.8.Genetic polymorphismstriglyceride .150 mg/dl Odds ratio 95 CI 0.087,0.921 0.081,3.583 0.373,10.cholesterol .200 mg/dlHOMA index .3.P value0.04 0.52 0.Odds ratio 1.360 7.373 0.95 CI 0.472,3.920 0.667,81.524 0.255,3.P value Odds ratio0.57 0.10 0.93 0.272 0.751 8.95 CI 0.049,1.517 0.112,5.063 1.573,49.P value0.14 0.77 0.PPARc C1430T (TC+TT) PPARc Pro12Ala (Pro/Ala) RBP4 2803GA (GA+AA)0.282 0.539 1.Variables of multivariate analysis include gender, age, C1430T polymorphism, P12A polymorphism, RBP4 polymorphism, hazardous drinking, HCV co-infection, calorie over-TEE, and efavirenz use. CI denotes confidence interval. doi:10.1371/journal.pone.0049102.tPPARc and RBP4 SNP on Metabolism in HIV Patients[14]. In HIV-infected patients, the association of C1431T polymorphism with metabolic syndrome is not well documented. For example, Nazih et al. found there was no convincing association between the His449His (equal to C1431T) polymorphism and individual components of the metabolic syndrome [40]. In the study by Zanone et al., the C161T (equal to C1431T) polymorphism had no influence on the presence of atrophy and fat accumulation in individuals with HIV-related lipodystrophy [41]. In our study, we found that the T allele of PPARc C1431T polymorphism was marginally associated with a lower rate of hypertriglyceridemia in HIV-infected patients receiving antiretroviral therapy in univariate and multivariate analyses. However, it did not reach a desirable power in the post hoc analysis and statistical significance after the correction for multiple testing. Finally, the statistical significance (0.006) with a nearly acceptable power (0.79) indicates that the T allele carriers have lower serum triglyceride levels at several time points of the longitudinal followup. There are many reasons to reduce the power of mixed models. For example: smaller sample size, lower number of repeated measures, higher between-subject variance, higher intraclass correlation, and smaller difference between two groups, and so on. Thus, the effect of PPARc C1431T polymorphism on serum triglyceride in HIV-infected patients is not significant and requires further large scale study. The Pro12Ala polymorphism in PPARc represents the first genetic variant with a broad impact on the risk and complications of type 2 diabetes. In vitro studies showed that Ala variant exhibited moderate reduction of target gene transactivation due to decreased DNA binding capacity [13]. The effect of the Ala carriage is not conclusive in the literature both in non HIV-infected and in HIVinfected patients. While most studies in non HIV-infected patients found that the Ala carrier exerted a protective effect from development of type 2 diabet.
